<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39432486</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of fecal microbiota transplantation for viral diseases: A systematic review of clinical trials.</ArticleTitle><Pagination><StartPage>e0311731</StartPage><MedlinePgn>e0311731</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0311731</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0311731</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gut microbiota play important roles in several diseases like viral infections. In this systematic review, our objective was to assess the efficacy and safety of fecal microbiota transplantation (FMT) in treating various viral diseases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted searches on databases including PubMed, Web of Science, Scopus, and Google Scholar until November 2023. Clinical trials reported outcomes related to safety of FMT or its efficacy in patients with viral diseases were included. We excluded other types of studies that enrolled healthy individuals or patients with other disorders and did not use FMT. The assessment of bias risk was conducted using the National Institutes of Health (NIH) study quality evaluation tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight studies with total 196 participants were included. Viral diseases were human immunodeficiency virus (HIV), hepatitis B, COVID-19 and Clostridioides difficile coinfection, and cytomegalovirus colitis. In hepatitis B cases, HBeAg clearance was significant in those received FMT (p&lt;0.01), while it was not significant in another one (p = 0.19). A clinical response was noted in 37.5% of patients with cytomegalovirus colitis, with an equal percentage achieving clinical remission post-FMT. There was a significant reduction in Clostridioides difficile relapse rate in FMT group than controls in coinfection of Clostridioides difficile and COVID-19 (2.17% vs. 42.5%, p&lt;0.05). In patients with HIV, partial engraftment of the donor microbiome and increases in alpha diversity were observed after FMT. No severe adverse events were reported. Most studies had fair or good qualities.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings revealed FMT as a promising, safe treatment for some viral diseases. It improved viral clearance, clinical outcomes, and inflammation. However, the varying responses and small sample sizes call for more trials on FMT in viral diseases.</AbstractText><CopyrightInformation>Copyright: © 2024 Ebrahimi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ebrahimi</LastName><ForeName>Rasoul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masouri</LastName><ForeName>Mohammad Mahdi</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salehi Amniyeh Khozani</LastName><ForeName>Amir Abbas</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadhan Hussein</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nejadghaderi</LastName><ForeName>Seyed Aria</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-8692-9720</Identifier><AffiliationInfo><Affiliation>HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="Y">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>13</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432486</ArticleId><ArticleId IdType="pmc">PMC11493255</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0311731</ArticleId><ArticleId IdType="pii">PONE-D-24-05937</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36. doi: 10.1042/BCJ20160510</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Karolewska-Bochenek K, Lazowska-Przeorek I, Grzesiowski P, Dziekiewicz M, Dembinski L, Albrecht P, et al.. Faecal Microbiota Transfer ‐ a new concept for treating cytomegalovirus colitis in children with ulcerative colitis. Ann Agric Environ Med. 2021;28(1):56–60. doi: 10.26444/aaem/118189</Citation><ArticleIdList><ArticleId IdType="doi">10.26444/aaem/118189</ArticleId><ArticleId IdType="pubmed">33775068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, et al.. Microbiota in health and diseases. Signal Transduction and Targeted Therapy. 2022;7(1):135. doi: 10.1038/s41392-022-00974-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00974-4</ArticleId><ArticleId IdType="pmc">PMC9034083</ArticleId><ArticleId IdType="pubmed">35461318</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–32. doi: 10.1038/nri.2017.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.7</ArticleId><ArticleId IdType="pubmed">28260787</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019;10:1551. doi: 10.3389/fimmu.2019.01551</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01551</ArticleId><ArticleId IdType="pmc">PMC6620863</ArticleId><ArticleId IdType="pubmed">31333675</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper A, Vijayakumar V, Ouwehand AC, ter Haar J, Obis D, Espadaler J, et al.. Viral Infections, the Microbiome, and Probiotics. Frontiers in Cellular and Infection Microbiology. 2021;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907522</ArticleId><ArticleId IdType="pubmed">33643929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizaka A, Koga M, Mizutani T, Parbie PK, Prawisuda D, Yusa N, et al.. Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiol Spectr. 2021;9(1):e0070821. doi: 10.1128/spectrum.00708-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00708-21</ArticleId><ArticleId IdType="pmc">PMC8552706</ArticleId><ArticleId IdType="pubmed">34378948</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi HY, Zhu X, Li WL, Mak JWY, Wong SH, Zhu ST, et al.. Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies. Eur J Nutr. 2021;60(8):4151–74. doi: 10.1007/s00394-021-02519-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-021-02519-x</ArticleId><ArticleId IdType="pmc">PMC8044287</ArticleId><ArticleId IdType="pubmed">33852069</ArticleId></ArticleIdList></Reference><Reference><Citation>Antushevich H. Fecal microbiota transplantation in disease therapy. Clinica Chimica Acta. 2020;503:90–8. doi: 10.1016/j.cca.2019.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2019.12.010</ArticleId><ArticleId IdType="pubmed">31968211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107(11):1755; author reply p.-6. doi: 10.1038/ajg.2012.251</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.251</ArticleId><ArticleId IdType="pubmed">23160295</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Cui B, He X, Nie Y, Wu K, Fan D, et al.. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein &amp; Cell. 2018;9(5):462–73. doi: 10.1007/s13238-018-0541-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-018-0541-8</ArticleId><ArticleId IdType="pmc">PMC5960466</ArticleId><ArticleId IdType="pubmed">29691757</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Zhang S, Quan J, Wu Z, Gu S, Chen Y, et al.. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model. Appl Microbiol Biotechnol. 2022;106(19–20):6689–700. doi: 10.1007/s00253-022-12154-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-022-12154-z</ArticleId><ArticleId IdType="pubmed">36085529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T, et al.. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716–23. doi: 10.1136/gutjnl-2020-323617</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323617</ArticleId><ArticleId IdType="pubmed">33785557</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Current Diabetes Reports. 2019;19(8):51. doi: 10.1007/s11892-019-1180-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-019-1180-z</ArticleId><ArticleId IdType="pubmed">31250122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartstra AV, Schüppel V, Imangaliyev S, Schrantee A, Prodan A, Collard D, et al.. Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome. Mol Metab. 2020;42:101076. doi: 10.1016/j.molmet.2020.101076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2020.101076</ArticleId><ArticleId IdType="pmc">PMC7536740</ArticleId><ArticleId IdType="pubmed">32916306</ArticleId></ArticleIdList></Reference><Reference><Citation>Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al.. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602. doi: 10.1126/science.abf3363</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf3363</ArticleId><ArticleId IdType="pmc">PMC8097968</ArticleId><ArticleId IdType="pubmed">33542131</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al.. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. Jama. 2019;321(2):156–64. doi: 10.1001/jama.2018.20046</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.20046</ArticleId><ArticleId IdType="pmc">PMC6439766</ArticleId><ArticleId IdType="pubmed">30644982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z, Xiong D, Shi J, Long M, Chen Z. The Interaction Between Viruses and Intestinal Microbiota: A Review. Curr Microbiol. 2021;78(10):3597–608. doi: 10.1007/s00284-021-02623-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-021-02623-5</ArticleId><ArticleId IdType="pmc">PMC8336530</ArticleId><ArticleId IdType="pubmed">34350485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Cai Y. Altered Gut Microbiota in HIV Infection: Future Perspective of Fecal Microbiota Transplantation Therapy. AIDS Res Hum Retroviruses. 2019;35(3):229–35. doi: 10.1089/AID.2017.0268</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/AID.2017.0268</ArticleId><ArticleId IdType="pubmed">29877092</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik A, Malik MI. Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis. Gastroenterology Res. 2023;16(4):209–16. doi: 10.14740/gr1624</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/gr1624</ArticleId><ArticleId IdType="pmc">PMC10482600</ArticleId><ArticleId IdType="pubmed">37691753</ArticleId></ArticleIdList></Reference><Reference><Citation>Caira-Chuquineyra B, Fernandez-Guzman D, Soriano-Moreno DR, Fernandez-Morales J F-LK, Medina-Ramírez SA, Gonzales-Uribe AG, et al.. Fecal Microbiota Transplantation for People Living with Human Immunodeficiency Virus: A Scoping Review. AIDS Research and Human Retroviruses. 2022;38(9):700–8. doi: 10.1089/AID.2022.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/AID.2022.0016</ArticleId><ArticleId IdType="pubmed">35451337</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. doi: 10.1371/journal.pmed.1003583</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003583</ArticleId><ArticleId IdType="pmc">PMC8007028</ArticleId><ArticleId IdType="pubmed">33780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddaway NR, Collins AM, Coughlin D, Kirk S. The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching. PLoS One. 2015;10(9):e0138237. doi: 10.1371/journal.pone.0138237</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138237</ArticleId><ArticleId IdType="pmc">PMC4574933</ArticleId><ArticleId IdType="pubmed">26379270</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH). National Heart, Lung, and Blood Institute (NHLBI), Study Quality Assessment Tools, Unites States; July, 2021 [Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools].</Citation></Reference><Reference><Citation>Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, Madrid N, Pérez-Molina JA, Elliott RJ, et al.. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nat Commun. 2021;12(1):1139. doi: 10.1038/s41467-021-21472-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21472-1</ArticleId><ArticleId IdType="pmc">PMC7892558</ArticleId><ArticleId IdType="pubmed">33602945</ArticleId></ArticleIdList></Reference><Reference><Citation>Boicean A, Neamtu B, Birsan S, Batar F, Tanasescu C, Dura H, et al.. Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and Clostridioides difficile. Biomedicines. 2022;11(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9855959</ArticleId><ArticleId IdType="pubmed">36672518</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A, Kumar R, Sharma S, Mahanta M, Vayuuru SK, Nayak B, et al.. Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. Dig Dis Sci. 2021;66(3):873–80. doi: 10.1007/s10620-020-06246-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06246-x</ArticleId><ArticleId IdType="pubmed">32279172</ArticleId></ArticleIdList></Reference><Reference><Citation>Utay NS, Monczor AN, Somasunderam A, Lupo S, Jiang ZD, Alexander AS, et al.. Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV. Pathog Immun. 2020;5(1):364–81. doi: 10.20411/pai.v5i1.388</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v5i1.388</ArticleId><ArticleId IdType="pmc">PMC7815055</ArticleId><ArticleId IdType="pubmed">33501400</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujkovic-Cvijin I, Rutishauser RL, Pao M, Hunt PW, Lynch SV, McCune JM, et al.. Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes. 2017;8(5):440–50. doi: 10.1080/19490976.2017.1334034</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2017.1334034</ArticleId><ArticleId IdType="pmc">PMC5628639</ArticleId><ArticleId IdType="pubmed">28541799</ArticleId></ArticleIdList></Reference><Reference><Citation>SahBandar IN, Chew GM, Corley MJ, Pang APS, Tsai N, Hanks N, et al.. Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade. Aids. 2020;34(10):1451–60. doi: 10.1097/QAD.0000000000002557</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002557</ArticleId><ArticleId IdType="pmc">PMC7371239</ArticleId><ArticleId IdType="pubmed">32675558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren YD, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, et al.. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology. 2017;65(5):1765–8. doi: 10.1002/hep.29008</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29008</ArticleId><ArticleId IdType="pubmed">28027582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu M, Tun KM, Batra K, Haque L, Vongsavath T, Hong AS. Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis. Microorganisms. 2023;11(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10224122</ArticleId><ArticleId IdType="pubmed">37317246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun KM, Hsu M, Batra K, Lo CH, Laeeq T, Vongsavath T, et al.. Efficacy and Safety of Fecal Microbiota Transplantation in Treatment of Clostridioides difficile Infection among Pediatric Patients: A Systematic Review and Meta-Analysis. Microorganisms. 2022;10(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9781859</ArticleId><ArticleId IdType="pubmed">36557703</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshan N, Clancy AK, Borody TJ. Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review. Infect Dis Ther. 2020;9(4):935–42. doi: 10.1007/s40121-020-00339-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00339-w</ArticleId><ArticleId IdType="pmc">PMC7680479</ArticleId><ArticleId IdType="pubmed">32979161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al.. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–43. doi: 10.1111/apt.13144</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13144</ArticleId><ArticleId IdType="pubmed">25728808</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al.. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15. doi: 10.1056/NEJMoa1205037</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1205037</ArticleId><ArticleId IdType="pubmed">23323867</ArticleId></ArticleIdList></Reference><Reference><Citation>Konturek PC, Koziel J, Dieterich W, Haziri D, Wirtz S, Glowczyk I, et al.. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol. 2016;67(6):859–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28195066</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Kristoffersen AB, Valeur J, Casen C, Hatlebakk JG, Gilja OH, et al.. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2022;34(1):e14200. doi: 10.1111/nmo.14200</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14200</ArticleId><ArticleId IdType="pubmed">34145677</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26(4):628–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">21323729</ArticleId></ArticleIdList></Reference><Reference><Citation>Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int. 2012;32(9):1333–41. doi: 10.1111/j.1478-3231.2012.02805.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2012.02805.x</ArticleId><ArticleId IdType="pubmed">22510145</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al.. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52(4):514–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20207438</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al.. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289–95. doi: 10.1136/gutjnl-2014-307023</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307023</ArticleId><ArticleId IdType="pubmed">25011935</ArticleId></ArticleIdList></Reference><Reference><Citation>Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al.. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755–64. doi: 10.1111/liv.13253</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.13253</ArticleId><ArticleId IdType="pubmed">27634134</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Chen Z, Zhou F, Chen L, He J, Xiao C, et al.. IDDF2018-ABS-0201 Faecal microbiota transplantation induced HBSAG decline in HBEAG negative chronic hepatitis B patients after long-term antiviral therapy2018. A110.2-A1 p.</Citation></Reference><Reference><Citation>Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16(9):1620–7. doi: 10.1002/ibd.21275</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21275</ArticleId><ArticleId IdType="pubmed">20232408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, et al.. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. The American Journal of Gastroenterology. 2001;96(3):773–5. doi: 10.1111/j.1572-0241.2001.03620.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2001.03620.x</ArticleId><ArticleId IdType="pubmed">11280549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones A, McCurdy JD, Loftus EV Jr, Bruining DH, Enders FT, Killian JM, et al.. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015;13(5):949–55. doi: 10.1016/j.cgh.2014.09.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2014.09.042</ArticleId><ArticleId IdType="pubmed">25283582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, et al.. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46(1):51–6. doi: 10.1097/MCG.0b013e3182160c9c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e3182160c9c</ArticleId><ArticleId IdType="pubmed">21552140</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, et al.. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96(7):2137–42. doi: 10.1111/j.1572-0241.2001.03949.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2001.03949.x</ArticleId><ArticleId IdType="pubmed">11467645</ArticleId></ArticleIdList></Reference><Reference><Citation>Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, et al.. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106(11):2001–8. doi: 10.1038/ajg.2011.202</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2011.202</ArticleId><ArticleId IdType="pubmed">21788989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla T, Singh S, Loftus EV Jr, Bruining DH, McCurdy JD. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015;21(11):2718–25. doi: 10.1097/MIB.0000000000000489</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000000489</ArticleId><ArticleId IdType="pubmed">26197450</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, et al.. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94(4):1053–6. doi: 10.1111/j.1572-0241.1999.01013.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.1999.01013.x</ArticleId><ArticleId IdType="pubmed">10201482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, et al.. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl):S59–65. doi: 10.1097/01.DCR.0000087486.21981.C6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.DCR.0000087486.21981.C6</ArticleId><ArticleId IdType="pubmed">14530660</ArticleId></ArticleIdList></Reference><Reference><Citation>Delvincourt M, Lopez A, Pillet S, Bourrier A, Seksik P, Cosnes J, et al.. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(7):712–20. doi: 10.1111/apt.12650</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12650</ArticleId><ArticleId IdType="pubmed">24506221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopylov U, Eliakim-Raz N, Szilagy A, Seidman E, Ben-Horin S, Katz L. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol. 2014;20(10):2695–703. doi: 10.3748/wjg.v20.i10.2695</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i10.2695</ArticleId><ArticleId IdType="pmc">PMC3949279</ArticleId><ArticleId IdType="pubmed">24627606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, et al.. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(6):741–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">26198180</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell GH, Kaplan JL, Youngster I, Baril-Dore M, Schindelar L, Hohmann E, et al.. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;58(5):588–92. doi: 10.1097/MPG.0000000000000283</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000283</ArticleId><ArticleId IdType="pubmed">24792627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature. 2013;498(7454):376–9. doi: 10.1038/nature12274</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12274</ArticleId><ArticleId IdType="pubmed">23739328</ArticleId></ArticleIdList></Reference><Reference><Citation>Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al.. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–14. doi: 10.1038/nature12940</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12940</ArticleId><ArticleId IdType="pmc">PMC4047036</ArticleId><ArticleId IdType="pubmed">24356306</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmentier M. CCR5 and HIV Infection, a View from Brussels. Frontiers in Immunology. 2015;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459230</ArticleId><ArticleId IdType="pubmed">26106394</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al.. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749–59. doi: 10.1084/jem.20040874</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20040874</ArticleId><ArticleId IdType="pmc">PMC2211962</ArticleId><ArticleId IdType="pubmed">15365096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E. The gut microbiome in human immunodeficiency virus infection. BMC Medicine. 2016;14(1):83. doi: 10.1186/s12916-016-0625-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0625-3</ArticleId><ArticleId IdType="pmc">PMC4891875</ArticleId><ArticleId IdType="pubmed">27256449</ArticleId></ArticleIdList></Reference><Reference><Citation>Utay NS, Overton ET. Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets. J Infect Dis. 2020;221(10):1567–70. doi: 10.1093/infdis/jiz351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz351</ArticleId><ArticleId IdType="pmc">PMC7184903</ArticleId><ArticleId IdType="pubmed">31282534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655–66. doi: 10.1038/nrmicro2848</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2848</ArticleId><ArticleId IdType="pubmed">22886237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al.. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228–38. doi: 10.1093/infdis/jiu238</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu238</ArticleId><ArticleId IdType="pmc">PMC4192038</ArticleId><ArticleId IdType="pubmed">24755434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al.. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90. doi: 10.1093/infdis/jiq118</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq118</ArticleId><ArticleId IdType="pmc">PMC3071127</ArticleId><ArticleId IdType="pubmed">21252259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al.. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59. doi: 10.1093/infdis/jiu254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu254</ArticleId><ArticleId IdType="pmc">PMC4192039</ArticleId><ArticleId IdType="pubmed">24795473</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al.. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71. doi: 10.1038/nm1511</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1511</ArticleId><ArticleId IdType="pubmed">17115046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ren R, Sun G, Peng L, Tian Y, Yang Y. Pilot study of cytokine changes evaluation after fecal microbiota transplantation in patients with ulcerative colitis. Int Immunopharmacol. 2020;85:106661. doi: 10.1016/j.intimp.2020.106661</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106661</ArticleId><ArticleId IdType="pubmed">32563025</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares-García L, Cárdenas-Barragán ME, Hernández-Ceballos W, Pérez-Solano CS, Morales-Guzmán AS, Miller DS, et al.. Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review. J Clin Gastroenterol. 2022;56(4):285–98. doi: 10.1097/MCG.0000000000001669</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001669</ArticleId><ArticleId IdType="pmc">PMC8900892</ArticleId><ArticleId IdType="pubmed">35125404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, et al.. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7(1):143. doi: 10.1038/s41392-022-00986-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00986-0</ArticleId><ArticleId IdType="pmc">PMC9052735</ArticleId><ArticleId IdType="pubmed">35487886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, et al.. Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. Clin Vaccine Immunol. 2017;24(8). doi: 10.1128/CVI.00037-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00037-17</ArticleId><ArticleId IdType="pmc">PMC5583471</ArticleId><ArticleId IdType="pubmed">28592627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonçalves LS, Gonçalves BM, Fontes TV. Periodontal disease in HIV-infected adults in the HAART era: Clinical, immunological, and microbiological aspects. Arch Oral Biol. 2013;58(10):1385–96. doi: 10.1016/j.archoralbio.2013.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2013.05.002</ArticleId><ArticleId IdType="pubmed">23755999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Fadrosh D, Ma B, Ravel J, Goedert JJ. Anal microbiota profiles in HIV-positive and HIV-negative MSM. AIDS. 2014;28(5):753–60. doi: 10.1097/QAD.0000000000000154</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000154</ArticleId><ArticleId IdType="pubmed">24335481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A, Bhattacharya H, Kandwal A. Probiotics in periodontal health and disease. J Indian Soc Periodontol. 2011;15(1):23–8. doi: 10.4103/0972-124X.82260</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-124X.82260</ArticleId><ArticleId IdType="pmc">PMC3134041</ArticleId><ArticleId IdType="pubmed">21772717</ArticleId></ArticleIdList></Reference><Reference><Citation>Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, et al.. Recovery of the gut microbiome following fecal microbiota transplantation. mBio. 2014;5(3):e00893–14. doi: 10.1128/mBio.00893-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00893-14</ArticleId><ArticleId IdType="pmc">PMC4068257</ArticleId><ArticleId IdType="pubmed">24939885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al.. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog. 2016;12(1):e1005349. doi: 10.1371/journal.ppat.1005349</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005349</ArticleId><ArticleId IdType="pmc">PMC4704737</ArticleId><ArticleId IdType="pubmed">26741490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirten RP, Grinspan A, Fu SC, Luo Y, Suarez-Farinas M, Rowland J, et al.. Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(6):969–79. doi: 10.1093/ibd/izy398</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izy398</ArticleId><ArticleId IdType="pmc">PMC6499938</ArticleId><ArticleId IdType="pubmed">30852592</ArticleId></ArticleIdList></Reference><Reference><Citation>Staley C, Kaiser T, Vaughn BP, Graiziger CT, Hamilton MJ, Rehman Tu, et al.. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome. 2018;6(1):166. doi: 10.1186/s40168-018-0549-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-018-0549-6</ArticleId><ArticleId IdType="pmc">PMC6145197</ArticleId><ArticleId IdType="pubmed">30227892</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou M, Jie Z, Cui B, Wang H, Feng Q, Zou Y, et al.. Fecal microbiota transplantation results in bacterial strain displacement in patients with inflammatory bowel diseases. FEBS Open Bio. 2020;10(1):41–55. doi: 10.1002/2211-5463.12744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12744</ArticleId><ArticleId IdType="pmc">PMC6943227</ArticleId><ArticleId IdType="pubmed">31622538</ArticleId></ArticleIdList></Reference><Reference><Citation>Folke C, Carpenter S, Walker B, Scheffer M, Elmqvist T, Gunderson L, et al.. Regime Shifts, Resilience, and Biodiversity in Ecosystem Management. Annual Review of Ecology, Evolution, and Systematics. 2004;35(1):557–81.</Citation></Reference><Reference><Citation>Tan XY, Xie YJ, Liu XL, Li XY, Jia B. A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Evid Based Complement Alternat Med. 2022;2022:8266793. doi: 10.1155/2022/8266793</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/8266793</ArticleId><ArticleId IdType="pmc">PMC9251102</ArticleId><ArticleId IdType="pubmed">35795291</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hausken T, Hatlebakk JG. Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(11):e14157. doi: 10.1111/nmo.14157</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14157</ArticleId><ArticleId IdType="pubmed">34236740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Chai J, Hammond K, Jeon SR, Patel Y, Goldeh C, et al.. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. Eur J Clin Microbiol Infect Dis. 2019;38(9):1731–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31165961</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Fu L, Li X, Lu C, Su Y, Xiong K, et al.. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study. Microb Cell Fact. 2021;20(1):18. doi: 10.1186/s12934-021-01513-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12934-021-01513-6</ArticleId><ArticleId IdType="pmc">PMC7816432</ArticleId><ArticleId IdType="pubmed">33468164</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021;53(1):33–42. doi: 10.1111/apt.16148</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16148</ArticleId><ArticleId IdType="pubmed">33159374</ArticleId></ArticleIdList></Reference><Reference><Citation>Elopre L, Rodriguez M. Fecal microbiota therapy for recurrent Clostridium difficile infection in HIV-infected persons. Ann Intern Med. 2013;158(10):779–80. doi: 10.7326/0003-4819-158-10-201305210-00021</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-10-201305210-00021</ArticleId><ArticleId IdType="pmc">PMC5908470</ArticleId><ArticleId IdType="pubmed">23689775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al.. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065–71. doi: 10.1038/ajg.2014.133</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.133</ArticleId><ArticleId IdType="pmc">PMC5537742</ArticleId><ArticleId IdType="pubmed">24890442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gweon TG, Kim J, Lim CH, Park JM, Lee DG, Lee IS, et al.. Fecal Microbiota Transplantation Using Upper Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated Clostridium difficile Infection in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. Gastroenterol Res Pract. 2016;2016:2687605. doi: 10.1155/2016/2687605</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2687605</ArticleId><ArticleId IdType="pmc">PMC4835647</ArticleId><ArticleId IdType="pubmed">27127501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al.. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):387–94. doi: 10.1093/ecco-jcc/jjv203</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjv203</ArticleId><ArticleId IdType="pmc">PMC4946755</ArticleId><ArticleId IdType="pubmed">26519463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramai D, Zakhia K, Ofosu A, Ofori E, Reddy M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol. 2019;32(1):30–8. doi: 10.20524/aog.2018.0328</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2018.0328</ArticleId><ArticleId IdType="pmc">PMC6302197</ArticleId><ArticleId IdType="pubmed">30598589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, et al.. Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(2):369–80. doi: 10.1007/s10620-020-06185-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06185-7</ArticleId><ArticleId IdType="pubmed">32166622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati M, Singh SK, Corrie L, Kaur IP, Chandwani L. Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. Pharmacol Res. 2020;159:104954. doi: 10.1016/j.phrs.2020.104954</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104954</ArticleId><ArticleId IdType="pubmed">32492490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>